Tsiporah B Shore

List of Publications by Year
in descending order

128 papers	2,855 citations	172457 29 h-index	189892 50 g-index
129 all docs	129 docs citations	129 times ranked	3834 citing authors

#	Article	IF	Citations
1	Adenovirus viremia after inÂvivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. Leukemia and Lymphoma, 2022, 63, 435-442.	1.3	2
2	C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplantation, 2022, 57, 1445-1447.	2.4	9
3	Predictors of Covid-19 Vaccination Response After In-Vivo T-Cellâ€"Depleted Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 618.e1-618.e10.	1.2	10
4	Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia and Lymphoma, 2021, 62, 1629-1638.	1.3	1
5	Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. Transplantation and Cellular Therapy, 2021, 27, 499.e1-499.e6.	1.2	2
6	Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities. Blood, 2021, 138, 1777-1777.	1.4	2
7	Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 1693-1700.	5.8	17
8	Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 789-797.	2.0	11
9	Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2020, 61, 3024-3026.	1.3	2
10	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. Ca-A Cancer Journal for Clinicians, 2020, 70, 349-354.	329.8	18
11	Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Advances, 2020, 4, 5146-5156.	5.2	5
12	Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplantation, 2020, 55, 2298-2307.	2.4	3
13	Seven Years of Haplo-Cord Transplantation: Immune Reconstitution and Outcomes Using Anti-Thymocyte Globulin. Biology of Blood and Marrow Transplantation, 2020, 26, S309.	2.0	1
14	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Advances, 2020, 4, 740-754.	5.2	42
15	532. COVID-19 Pneumonia in Patients with Hematologic Malignancies â€" A Report from the US Epicenter. Open Forum Infectious Diseases, 2020, 7, S333-S333.	0.9	0
16	A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas. Blood, 2020, 136, 7-8.	1.4	3
17	Clinical Characteristics and Risk Factors for Adverse Outcomes of Influenza Infections in Hematopoietic Stem Cell Transplant Recipients. Blood, 2020, 136, 22-22.	1.4	0
18	A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). Biology of Blood and Marrow Transplantation, 2019, 25, 1984-1992.	2.0	25

#	Article	IF	Citations
19	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2027-2038.	2.4	20
20	Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leukemia and Lymphoma, 2019, 60, 1693-1696.	1.3	22
21	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Advances, 2019, 3, 1858-1867.	5.2	25
22	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biology of Blood and Marrow Transplantation, 2019, 25, 466-473.	2.0	4
23	Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. Biology of Blood and Marrow Transplantation, 2019, 25, e60-e64.	2.0	13
24	A Case Report of the Benefit of Cannabidiol (Cannabidiol (CBD)-Predominant Medical Cannabis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54 5687-5687.	1.4	0
25	Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cellsâ€"a singleâ€institution experience. Transfusion, 2018, 58, 339-344.	1.6	2
26	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation, 2018, 24, 997-1004.	2.0	18
27	Colonization With Levofloxacin-resistant Extended-spectrum Î²-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2018, 67, 1720-1728.	5.8	34
28	Acute myeloid leukemia in a patient with thrombocytopenia with absent radii: A case report and review of the literature. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 245-247.	0.9	13
29	Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biology of Blood and Marrow Transplantation, 2018, 24, 288-293.	2.0	13
30	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 359-365.	2.0	20
31	1581. Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin. Open Forum Infectious Diseases, 2018, 5, S494-S494.	0.9	0
32	Hematopoietic Recovery after in-Vivo T-Cell Depleted Allogeneic Stem Cell Transplant-Effects of Major ABO Incompatibility, CMV Viremia and Acute Gvhd. Biology of Blood and Marrow Transplantation, 2018, 24, S337.	2.0	0
33	Safety and efficacy of plerixafor dose escalation for the mobilization of CD34 ⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica, 2018, 103, 770-777.	3.5	47
34	Final results from a defibrotide treatmentâ€<scp>IND</scp> study for patients with hepatic venoâ€occlusive disease/sinusoidal obstruction syndrome. British Journal of Haematology, 2018, 181, 816-827.	2.5	95
35	Kidney Dysfunction Post-Allogeneic Transplant: High Incidence of TMA and Kidney GvHD. Biology of Blood and Marrow Transplantation, 2018, 24, S209-S210.	2.0	0
36	Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?. Blood, 2018, 132, 2172-2172.	1.4	1

#	Article	IF	Citations
37	Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma. Blood, 2018, 132, 1640-1640.	1.4	0
38	CCR5 delta32 Cord & Haploidentical Grafts: Allogeneic Stem Cell Transplant for HIV+ /AML Patient: A Case Report from the Impaact P1107 Observational Study. Blood, 2018, 132, 2184-2184.	1.4	0
39	Cord blood chimerism and relapse after haplo-cord transplantation. Leukemia and Lymphoma, 2017, 58, 288-297.	1.3	17
40	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 930-937.	2.0	10
41	The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation, 2017, 101, e34-e38.	1.0	14
42	Bortezomib and Immune Globulin Desensitization for Donor-Specific HLA Antibodies in Haplo-Cord Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, S265.	2.0	3
43	Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biology of Blood and Marrow Transplantation, 2017, 23, 997-1004.	2.0	47
44	Haplo-cord transplant: HLA-matching determines graft dominance. Leukemia and Lymphoma, 2017, 58, 1512-1514.	1.3	7
45	Coronavirus Infection in Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2017, 4, S730-S731.	0.9	0
46	Studies of White Cell, Platelet, and Coagulation Activation with Plerixafor Administration in Patients with Sickle Cell Disease. Blood, 2017, 130, 963-963.	1.4	2
47	Colonization with Vancomycin-Resistant Enterococci and Subsequent Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.9	2
48	Impact of Levofloxacin Prophylaxis on Rates of Bloodstream Infection and Fever and Neutropenia in Autologous Stem Cell Transplant Recipients with Lymphoma. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
49	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 297-303.	0.4	19
50	Bendamustine and stem-cell mobilization: not so bad!. Leukemia and Lymphoma, 2016, 57, 993-994.	1.3	0
51	DAS181 for Treatment of Parainfluenza Virus Infections inÂHematopoietic Stem Cell Transplant Recipients at a Single Center. Biology of Blood and Marrow Transplantation, 2016, 22, 965-970.	2.0	52
52	Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial. Biology of Blood and Marrow Transplantation, 2016, 22, S23.	2.0	34
53	Comparison of Subcutaneous Versus Intravenous Alemtuzumab for Graft-Versus-Host Disease Prophylaxis with Fludarabine/Melphalan Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2016, 22, S478.	2.0	0
54	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation, 2016, 22, 1197-1205.	2.0	17

#	Article	IF	Citations
55	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica, 2016, 101, 634-643.	3.5	30
56	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1348-1356.	2.0	76
57	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 1065-1072.	2.0	20
58	Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. Leukemia and Lymphoma, 2016, 57, 2555-2559.	1.3	12
59	Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalanâ€“Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 456-461.	2.0	18
60	Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 3496-3496.	1.4	0
61	Enlarged Spleen Prior to Allogeneic Transplantation for Myelofibrosis Is Associated with Poor Engraftment and Increased Non-Relapse Mortality. Biology of Blood and Marrow Transplantation, 2015, 21, S285.	2.0	1
62	A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion, 2015, 55, 2010-2016.	1.6	15
63	How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. Transfusion, 2015, 55, 1147-1153.	1.6	18
64	Colonization With Extended-Spectrum Î²-Lactamase-Producing Enterobacteriaceae and Subsequent Risk of Bacteremia in Neutropenic Patients Undergoing Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases, 2015, 2, .	0.9	1
65	Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1808-1814.	2.0	49
66	Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. Journal of Clinical Virology, 2015, 71, 51-58.	3.1	36
67	Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a singleâ€centre study with focus on emerging pathogens. Mycoses, 2015, 58, 325-336.	4.0	94
68	Predictors and GVL Effects of UCB Chimerism after Haplo-Cord Transplant. Blood, 2015, 126, 4385-4385.	1.4	2
69	Time until Transfusion Independence in Haplo-Cord Transplant Is Comparable to Matched Unrelated Stem Cell Transplant, a Single Institution Experience. Blood, 2015, 126, 4331-4331.	1.4	0
70	The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leukemia and Lymphoma, 2014, 55, 2858-2865.	1.3	30
71	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. Journal of Clinical Oncology, 2014, 32, 3264-3274.	1.6	146
72	Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, S162.	2.0	3

#	Article	IF	Citations
73	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood, 2014, 124, 1183-1191.	1.4	135
74	Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. Blood, 2014, 124, 1093-1093.	1.4	4
75	Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50. Blood, 2014, 124, 1235-1235.	1.4	3
76	Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood, 2014, 124, 501-501.	1.4	9
77	CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a â€œtest doseâ€• Strategy to Target Busulfan Exposure. Blood, 2014, 124, 543-543.	1.4	6
78	Haplo+cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantationâ€”A case-cohort analysis.. Journal of Clinical Oncology, 2014, 32, 7004-7004.	1.6	4
79	Abstract CT413: Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumors. Cancer Research, 2014, 74, CT413-CT413.	0.9	1
80	Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clinical Advances in Hematology and Oncology, 2014, 12, 565-73.	0.3	30
81	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation inÂMultiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 831-837.	2.0	29
82	Avoiding pitfalls in bone marrow engraftment analysis: a case study highlighting the weakness of using buccal cells for determining a patient's constitutional genotype after hematopoietic stem cell transplantation. Cytotherapy, 2013, 15, 391-395.	0.7	9
83	Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leukemia and Lymphoma, 2013, 54, 885-888.	1.3	6
84	Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America. Biology of Blood and Marrow Transplantation, 2013, 19, S132.	2.0	5
85	Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leukemia and Lymphoma, 2013, 54, 799-806.	1.3	111
86	A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia. Biology of Blood and Marrow Transplantation, 2013, 19, 1040-1045.	2.0	17
87	Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clinical Cancer Research, 2013, 19, 1534-1546.	7.0	22
88	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. Blood, 2013, 122, 768-768.	1.4	0
89	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145.	1.4	0
90	Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 1469-1473.	1.3	21

#	Article	IF	Citations
91	Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic Precursor Cell Enumeration with First-Harvest CD34+ Stem Cell Yield. Biology of Blood and Marrow Transplantation, 2012, 18, 1867-1875.	2.0	12
92	Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. American Journal of Hematology, 2012, 87, 433-435.	4.1	38
93	Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population. Blood, 2012, 120, 4269-4269.	1.4	0
94	Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America. Blood, 2012, 120, 813-813.	1.4	0
95	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. Blood, 2011, 118, 1750-1750.	1.4	2
96	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma. Blood, 2011, 118, 2042-2042.	1.4	1
97	Bone Marrow Engraftment Analysis. , 2011, , 147-157.		0
98	A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia. Blood, 2011, 118, 3030-3030.	1.4	0
99	Effectiveness and Safety of Tocilizumab, an Antiâ€“Interleukin-6 Receptor Monoclonal Antibody, in a Patient With Refractory GI Graft-Versus-Host Disease. Journal of Clinical Oncology, 2010, 28, e602-e604.	1.6	38
100	Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 192-196.	0.4	53
101	A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory leukemia.. Blood, 2010, 116, 1334-1334.	1.4	1
102	A Comparison of Chemotherapy + G-CSF Versus Plerixafor (MozobilÂ®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide. Blood, 2010, 116, 2258-2258.	1.4	1
103	A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma. PLoS ONE, 2010, 5, e8714.	2.5	9
104	Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities. Blood, 2010, 116, 3561-3561.	1.4	1
105	Clinical and Ultrasonic Evaluation of Spleen Size during Peripheral Blood Progenitor Cell Mobilization by Filgrastim: Results of an Open-Label Trial in Normal Donors. Biology of Blood and Marrow Transplantation, 2009, 15, 827-834.	2.0	17
106	The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.. Blood, 2009, 114, 4349-4349.	1.4	0
107	Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Supportive Care in Cancer, 2008, 16, 477-483.	2.2	18
108	Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2008, 14, 795-798.	2.0	106

#	Article	IF	Citations
109	Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. Journal of Clinical Oncology, 2008, 26, 37-43.	1.6	53
110	BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood, 2008, 111, 1101-1109.	1.4	175
111	Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leukemia and Lymphoma, 2007, 48, 342-348.	1.3	12
112	Stem cell transplantation for myelodysplastic syndromes: The lure of a cure. Current Hematologic Malignancy Reports, 2007, 2, 3-8.	2.3	0
113	Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. Blood, 2007, 110, 3024-3024.	1.4	1
114	A Study of a Reduced-Intensity Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies Using Campath-1H as Part of a Graft-versus-Host Disease Strategy. Biology of Blood and Marrow Transplantation, 2006, 12, 868-875.	2.0	15
115	Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer, 2006, 106, 616-622.	4.1	40
116	Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46 2751-2751.	1.4	7
117	Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma.. Blood, 2006, 108, 2953-2953.	1.4	3
118	Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2005, 23, 5044-5051.	1.6	164
119	Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).. Blood, 2005, 106, 1856-1856.	1.4	3
120	Epidemiology of Adult Acute Lymphoblastic Leukemia in Manitoba, Canada: Does This Approximate Clinical Trial Data?.. Blood, 2005, 106, 4554-4554.	1.4	0
121	An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biology of Blood and Marrow Transplantation, 2004, 10, 405-414.	2.0	61
122	Phase I Trial of CG53135-05 to Prevent Mucositis in Patients Undergoing High-Dose Chemotherapy (HDCT) and Autologous Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2004, 104, 1161-1161.	1.4	0
123	HHV-6 Reactivation after Autologous Stem Cell Transplantation Is Associated with Prolonged Hospitalization but Not with Delayed Engraftment.. Blood, 2004, 104, 3168-3168.	1.4	0
124	Washing Stem Cells Cryopreserved in Dimethyl Sulfoxide (DMSO) before Infusion Prevents DMSO-Related Side Effects with Little Loss of CD34 Positive Cells and Prompt Engraftment.. Blood, 2004, 104, 4998-4998.	1.4	1
125	A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood, 2002, 100, 1525-1531.	1.4	315
126	Remission induction therapy of untreated acute myeloid leukemia using a nonâ€cytarabineâ€containing regimen of idarubicin, etoposide, and carboplatin. Cancer, 1998, 83, 1344-1354.	4.1	0

#	Article	IF	Citations
127	A meta-analysis of stages I and II Hodgkin's disease. Cancer, 1990, 65, 1155-1160.	4.1	40
128	The predictive value of in-vitro techniques in acute non-lymphocytic leukemia. Leukemia Research, 1987, 11, 687-691.	0.8	1